Immuneering (IMRX) director receives 33,350 stock options at $4.12 strike

Rhea-AI Filing Summary

Immuneering Corp director Thomas J. Schall received a grant of stock options covering 33,350 shares of Class A common stock at an exercise price of $4.12 per share. The options vest in equal monthly installments over one year starting on July 11, 2026.

The award will be fully vested by June 11, 2027 or on the date of the 2027 annual meeting of stockholders, whichever occurs first. This is a compensation-related equity grant rather than an open-market stock purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Schall Thomas J.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	33,350	$0.00	--

Holdings After Transaction: Stock Option — 33,350 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 33,350 options Exercise price: $4.12 per share Underlying shares: 33,350 shares +3 more

6 metrics

Stock options granted 33,350 options Grant to director Thomas J. Schall

Exercise price $4.12 per share Stock option strike price

Underlying shares 33,350 shares Class A common stock underlying the options

Expiration date June 11, 2036 Option expiration if unexercised

Vesting start July 11, 2026 Monthly vesting commencement date

Full vest date June 11, 2027 Or 2027 annual meeting date, whichever first

Key Terms

Stock Option, Class A Common Stock, exercise price, vesting, +1 more

5 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Class A Common Stock financial

"underlying_security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion_or_exercise_price: "4.1200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests and becomes exercisable in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"or the date of the 2027 annual meeting of stockholders, whichever comes first"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schall Thomas J.

(Last) (First) (Middle)

C/O IMMUNEERING CORPORATION

245 MAIN STREET, 2ND FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$4.12	06/11/2026		A		33,350		(1)	06/11/2036	Class A Common Stock	33,350	$0	33,350	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Thomas J. Schall	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Immuneering Corp (IMRX) report for Thomas J. Schall?

Immuneering Corp reported a stock option grant to director Thomas J. Schall. He received options for 33,350 shares of Class A common stock as a compensation award, not through an open-market purchase or sale, according to the Form 4 filing details.

How many Immuneering (IMRX) stock options were granted to Thomas J. Schall and at what price?

Thomas J. Schall was granted 33,350 stock options at an exercise price of $4.12 per share. These options relate to Class A common stock and were issued as a grant/award acquisition, with no cash paid at the time of the grant.

When do Thomas J. Schall’s Immuneering (IMRX) stock options vest?

The stock options vest in equal monthly installments over one year. Vesting starts on July 11, 2026, and the options will be fully vested by June 11, 2027, or on the date of the 2027 annual meeting of stockholders, whichever comes first.

Is the Immuneering (IMRX) Form 4 transaction a stock sale or purchase?

The Form 4 shows a compensation grant, not a market trade. The transaction is coded as a grant or award acquisition of stock options, meaning no open-market buying or selling of Immuneering shares occurred in this filing.

What type of security did Immuneering (IMRX) grant to Thomas J. Schall?

Immuneering granted a stock option linked to Class A common stock. The option covers 33,350 underlying shares and carries an exercise price of $4.12 per share, expiring on June 11, 2036, if not exercised earlier after vesting.